Axovant Sciences (AXON) Hits New 12-Month Low at $0.93

Axovant Sciences Ltd (NASDAQ:AXON) shares hit a new 52-week low on Friday . The stock traded as low as $0.93 and last traded at $1.06, with a volume of 70095 shares. The stock had previously closed at $1.13.

AXON has been the topic of several recent analyst reports. ValuEngine upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Zacks Investment Research lowered shares of Axovant Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th. Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a research report on Sunday, November 11th. BidaskClub upgraded shares of Axovant Sciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 1st. Finally, Cowen reiterated a “hold” rating on shares of Axovant Sciences in a research report on Thursday, September 20th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. Axovant Sciences presently has an average rating of “Hold” and a consensus target price of $4.56.

The company has a debt-to-equity ratio of 1.68, a current ratio of 1.97 and a quick ratio of 1.97.



Hedge funds have recently added to or reduced their stakes in the company. Paloma Partners Management Co acquired a new stake in shares of Axovant Sciences in the second quarter valued at approximately $356,000. Tower Research Capital LLC TRC grew its position in shares of Axovant Sciences by 1,627.0% in the second quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 58,541 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Axovant Sciences during the second quarter worth approximately $338,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in Axovant Sciences by 12.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 559,602 shares of the biotechnology company’s stock worth $1,354,000 after acquiring an additional 64,152 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Axovant Sciences by 60.5% during the third quarter. Renaissance Technologies LLC now owns 2,091,700 shares of the biotechnology company’s stock worth $5,062,000 after acquiring an additional 788,100 shares during the last quarter. Institutional investors and hedge funds own 7.71% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://dakotafinancialnews.com/2018/12/16/axovant-sciences-axon-hits-new-12-month-low-at-0-93.html.

Axovant Sciences Company Profile (NASDAQ:AXON)

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

Read More: Asset Allocation, Balancing Your Investments

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply